Previous Article | Next Article ![]()
Journal of Virology, October 1998, p. 7840-7845, Vol. 72, No. 10
Aaron Diamond AIDS Research Center, The
Rockefeller University, New York, New York 10021-6399
Received 8 April 1998/Accepted 28 June 1998
SF162 is a primary (PR), non-syncytium-inducing, macrophagetropic
human immunodeficiency virus type 1 (HIV-1) clade B isolate which is
resistant to antibody-mediated neutralization. Deletion of the first or
second hypervariable envelope gp120 region (V1 or V2 loop,
respectively) of this virus does not abrogate its ability to
replicate in peripheral blood mononuclear cells and primary
macrophages, nor does it alter its coreceptor usage profile. The mutant
virus with the V1 loop deletion, SF162
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
An Envelope Modification That Renders a Primary,
Neutralization-Resistant Clade B Human Immunodeficiency Virus Type
1 Isolate Highly Susceptible to Neutralization by Sera from
Other Clades
V1, remains as resistant to
antibody-mediated neutralization as the wild-type virus
SF162. In contrast, the mutant virus with the V2 loop deletion, SF162
V2, exhibits enhanced susceptibility to neutralization by certain monoclonal antibodies whose epitopes are located within the
CD4-binding site and conserved regions of gp120. More importantly, SF162
V2 is now up to 170-fold more susceptible to
neutralization than SF162 by sera collected from patients infected with
clade B HIV-1 isolates. In addition, it becomes susceptible to
neutralization by sera collected from patients infected with clade A,
C, D, E, and F HIV-1 isolates. These findings suggest that the V2, but not the V1, loop of SF162 shields an as yet unidentified region of the
HIV envelope rich in neutralization epitopes and that the overall
structure of this region appears to be conserved among clade B, C, D,
E, and F HIV-1 PR isolates.
*
Corresponding author. Mailing address: Aaron Diamond
AIDS Research Center, 455 First Ave., 7th floor, New York, NY 10016. Phone: (212) 725-0018. Fax: (212) 448-5159. E-mail:
leonidas{at}adarc.org.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|